Erythrokeratodermia Variabilis et Progressiva

Erythrokeratodermia Variabilis et Progressiva

No Results

No Results


The clinically and genetically heterogeneous group of erythrokeratodermas encompasses several rare genetic skin disorders, including autosomal dominant erythrokeratodermia variabilis (EKV) and progressive symmetric erythrokeratoderma (PSEK) (OMIM # 133200), as well as autosomal dominant spinocerebellar ataxia with erythrokeratodermia (Giroux and Barbeau; SCA34;OMIM # 133190). The skin lesions of EKV and PSEK show many similarities, and a small subset of patients with features previously considered to be PSEK share the underlying cause of EKV. Therefore, it was recently proposed to classify this disorder as erythrokeratodermia variabilis et progressiva (EKVP). [1] Nevertheless, PSEK and overlapping forms of erythrokeratoderma do exist as genetically distinct and heterogeneous entities from EKVP.

EKVP is characterized by the coexistence of two distinct morphologic features: hyperkeratosis and transient erythema, albeit one of these features may predominate. de Buy Wenninger recognized and described the first cases of erythrokeratodermia variabilis in the Netherlands in 1907. [2] In 1925, Mendes da Costa presented a detailed clinical description of the disease in a mother and daughter, reviewed eight similar cases that were previously published, and coined the name “erythro- et keratodermia variabilis.” [3] During the next decades, multiple case reports emerged in the Northern European literature, including a study of 33 affected members of a Dutch family and 29 affected persons in 5 generations of a Swiss family. [4] In 1964, Barsky and Bernstein reported the first case in the American literature. [5] The first family in which affected members had features of either EKV or PSEK was reported in 1991. [6]

Erythrokeratodermia variabilis et progressiva (EKVP) is an inherited disorder of cornification associated with noninflammatory erythema. Marked hyperkeratosis is present, probably because of an increased proliferation and disturbed differentiation of keratinocytes.

Approximately two thirds of cases of EKVP are caused by heterozygous missense variants in the connexin genes GJB3, encoding connexin-31 (Cx31), and GJB4, encoding connexin-30.3 (Cx30.3). In rare cases, pathogenic missense changes in the GJA1 gene encoding connexin-43 (Cx43) have been reported. [7] Connexins are a family of transmembrane proteins that assemble into hexameric hemichannels and form gated intercellular gap junction channels. The finding of mutations in GJB3, GJB4, and GJA1 suggests that the clinical manifestations of EKVP are caused by impaired gap junctional intercellular communication or hemichannel function owing to a dominant effect of mutant gap junction proteins. [8, 9]

Erythrokeratodermia variabilis et progressiva (EKVP) is rare, and its accurate prevalence is not known. More than 200 cases are reported in patients with diverse genetic backgrounds. Fifty-four affected individuals from 16 families were known to the author in the United States in 2004.

EKVP has been reported worldwide. Most cases were whites of Northern and Middle European origin, but erythrokeratodermia variabilis also occurs in African Americans and Asians.

Both sexes are affected equally.

More than 50% of patients present with symptoms at birth or in the neonatal period. Approximately 90% of patients present with EKVP within the first year of life. In general, onset of disease is earlier in individuals with severe disease, including generalized hyperkeratosis.

Erythrokeratodermia variabilis et progressiva (EKVP) is a chronic skin disorder without other organ manifestations; patients have a normal life expectancy. If properly treated, the skin manifestations of EKVP can be well controlled. Depending on the extent and severity of erythrokeratodermia variabilis, the skin lesions also can be severely disfiguring and have a tremendous psychosocial effect on the patients. In addition, the erythematous patches may diminish as the patient ages. Generalized hyperkeratosis may be associated with heat intolerance.

Patients of childbearing age should receive genetic counseling. Molecular diagnostic testing for mutations in the connexin genes GJB3,GJB4, and GJA1 is available. The results of such analysis will allow for appropriate genetic counseling of the patient and family, particularly with respect to recurrence risk in future pregnancies.

Triggering events, such as exposure to cold, drastic temperature changes, and mechanical irritation of the skin, should be avoided. Patients with generalized hyperkeratosis should be informed about the possibility of heat intolerance.

The Foundation for Ichthyosis and Related Skin Types, F.I.R.S.T., is a patient advocacy group that offers information, educational materials, and support for patients and their families.

Cadieux-Dion M, Turcotte-Gauthier M, Noreau A, Martin C, Meloche C, Gravel M, et al. Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. JAMA Neurol. 2014 Apr. 71 (4):470-5. [Medline].

de Buy Wenninger LM. Erythrokeratodermie congenitale ichthyosiforme avec hyperepidermotrophie. Verslagen van vereeningingene. Nederl Tijdschr Geneesk. 1907. 1A:510-5.

Mendes da Costa S. Erythro et keratodermia variabilis in a mother and a daughter. Acta Derm Venerol. 1925. 6:255-61.

Noordhoek KJ. Over erythro-et keratodermia variabilis. Schiedam NV, ed. Drukkererije de Eendracht. Utrecht, The Netherlands: 1950.

Barsky S, Bernstein G. Keratosis Rubra Figurata. Arch Dermatol. 1964. 90:373-4.

Macfarlane AW, Chapman SJ, Verbov JL. Is erythrokeratoderma one disorder? A clinical and ultrastructural study of two siblings. Br J Dermatol. 1991 May. 124(5):487-91. [Medline].

Boyden LM, Craiglow BG, Zhou J, Hu R, Loring EC, Morel KD, et al. Dominant De Novo Mutations in GJA1 Cause Erythrokeratodermia Variabilis et Progressiva, without Features of Oculodentodigital Dysplasia. J Invest Dermatol. 2015 Jun. 135 (6):1540-7. [Medline].

Fuchs-Telem D, Pessach Y, Mevorah B, Shirazi I, Sarig O, Sprecher E. Erythrokeratoderma variabilis caused by a recessive mutation in GJB3. Clin Exp Dermatol. 2011 Jun. 36(4):406-11. [Medline].

Wei S, Zhou Y, Zhang TD, Huang ZM, Zhang XB, Zhu HL, et al. Evidence for the absence of mutations at GJB3, GJB4 and LOR in progressive symmetrical erythrokeratodermia. Clin Exp Dermatol. 2011 Jun. 36(4):399-405. [Medline].

Umegaki-Arao N, Sasaki T, Fujita H, Aoki S, Kameyama K, Amagai M, et al. Inflammatory Linear Verrucous Epidermal Nevus with a Postzygotic GJA1 Mutation Is a Mosaic Erythrokeratodermia Variabilis et Progressiva. J Invest Dermatol. 2017 Apr. 137 (4):967-970. [Medline].

Common JE, O’Toole EA, Leigh IM, et al. Clinical and genetic heterogeneity of erythrokeratoderma variabilis. J Invest Dermatol. 2005 Nov. 125(5):920-7. [Medline].

Richard G, Brown N, Smith LE, et al. The spectrum of mutations in erythrokeratodermias–novel and de novo mutations in GJB3. Hum Genet. 2000 Mar. 106(3):321-9. [Medline].

Richard G, Itin P, Bale SJ. Clinical heterogeneity in EKV. J Invest Dermatol. 1998. 110:616A.

Feldmeyer L, Plantard L, Mevorah B, Huber M, Hohl D. Novel mutation of connexin 31 causing erythrokeratoderma variabilis. Br J Dermatol. 2005 May. 152(5):1072-4. [Medline].

Gottfried I, Landau M, Glaser F, et al. A mutation in GJB3 is associated with recessive erythrokeratodermia variabilis (EKV) and leads to defective trafficking of the connexin 31 protein. Hum Mol Genet. 2002 May 15. 11(11):1311-6. [Medline].

Macari F, Landau M, Cousin P, et al. Mutation in the gene for connexin 30.3 in a family with erythrokeratodermia variabilis. Am J Hum Genet. 2000 Nov. 67(5):1296-301. [Medline].

Plantard L, Huber M, Macari F, Meda P, Hohl D. Molecular interaction of connexin 30.3 and connexin 31 suggests a dominant-negative mechanism associated with erythrokeratodermia variabilis. Hum Mol Genet. 2003 Dec 15. 12(24):3287-94. [Medline].

Renner R, Paasch U, Simon JC, Froster UG, Heinritz W. A new mutation in the GJB3 gene in a patient with erythrokeratodermia variabilis. J Eur Acad Dermatol Venereol. 2008 Jun. 22(6):750-1. [Medline].

Richard G, Brown N, Rouan F, et al. Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. J Invest Dermatol. 2003 Apr. 120(4):601-9. [Medline].

Richard G, Smith LE, Bailey RA, et al. Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat Genet. 1998 Dec. 20(4):366-9. [Medline].

Terrinoni A, Leta A, Pedicelli C, et al. A novel recessive connexin 31 (GJB3) mutation in a case of erythrokeratodermia variabilis. J Invest Dermatol. 2004 Mar. 122(3):837-9. [Medline].

Wilgoss A, Leigh IM, Barnes MR, et al. Identification of a novel mutation R42P in the gap junction protein beta-3 associated with autosomal dominant erythrokeratoderma variabilis. J Invest Dermatol. 1999 Dec. 113(6):1119-22. [Medline].

Wang ZX, Lu WS, Li H, Lin D, Zhou FS, Sun LD, et al. A novel GJB3 (Cx31) missense mutation in a Chinese patient with erythrokeratodermia variabilis. J Eur Acad Dermatol Venereol. 2011 Jan. 25(1):113-5. [Medline].

Scott CA, O’Toole EA, Mohungoo MJ, Messenger A, Kelsell DP. Novel and recurrent connexin 30.3 and connexin 31 mutations associated with erythrokeratoderma variabilis. Clin Exp Dermatol. 2011 Jan. 36(1):88-90. [Medline].

Glatz M, van Steensel MA, van Geel M, Steijlen PM, Wolf P. An unusual missense mutation in the GJB3 gene resulting in severe erythrokeratodermia variabilis. Acta Derm Venereol. 2011 Oct. 91(6):714-5. [Medline].

Sugiura K, Arima M, Matsunaga K, Akiyama M. The novel GJB3 mutation p.Thr202Asn in the M4 transmembrane domain underlies erythrokeratodermia variabilis. Br J Dermatol. 2015 Jul. 173 (1):309-11. [Medline].

Ikeya S, Urano S, Sakabe J, Ito T, Tokura Y. Erythrokeratodermia variabilis: first Japanese case documenting GJB3 mutation. J Dermatol. 2013 May. 40 (5):402-3. [Medline].

Liu H, Liu H, Fu XA, Yu YX, Zhou GZ, Lu XM, et al. Mutation analysis of GJB3 and GJB4 in Chinese patients with erythrokeratodermia variabilis. J Dermatol. 2012 Apr. 39 (4):400-1. [Medline].

Torres T, Velho G, Sanches M, Selores M. A case of erythrokeratodermia variabilis with connexin 31 gene mutation (Cx31F137L). Int J Dermatol. 2012 Apr. 51 (4):494-6. [Medline].

Wang W, Liu LH, Chen G, Gao M, Zhu J, Zhou FS, et al. A missense mutation in the GJB3 gene responsible for erythrokeratodermia variabilis in a Chinese family. Clin Exp Dermatol. 2012 Dec. 37 (8):919-21. [Medline].

Yoshikata-Isokawa Y, Itoh M, Nakagawa H. Japanese sporadic case of erythrokeratodermia variabilis caused by the connexin-30.3 (GJB4) mutation: Is Glycine 12 a mutational hotspot in the connexin family?. J Dermatol. 2016 Jul. 43 (7):830-1. [Medline].

Sugiura K, Arima M, Matsunaga K, Akiyama M. The novel GJB3 mutation p.Thr202Asn in the M4 transmembrane domain underlies erythrokeratodermia variabilis. Br J Dermatol. 2015 Jul. 173 (1):309-11. [Medline].

Otaguchi R, Kawakami T, Matsuoka M, Kimura S, Soma Y, Matsuda M, et al. A sporadic elder case of erythrokeratodermia variabilis with a single base-pair transversion in GJB3 gene successfully treated with systemic vitamin A derivative. J Dermatol. 2014 Nov. 41 (11):1016-8. [Medline].

Arita K, Akiyama M, Tsuji Y, Onozuka T, Shimizu H. Erythrokeratoderma variabilis without connexin 31 or connexin 30.3 gene mutation: immunohistological, ultrastructural and genetic studies. Acta Derm Venereol. 2003. 83(4):266-70. [Medline].

Nakamura M. Erythrokeratoderma variabilis without GJB3 or GJB4 mutation: a review of Japanese patients. Br J Dermatol. 2007 Aug. 157(2):410-1. [Medline].

Zhou F, Fu H, Liu L, Cui Y, Zhang Z, Chang R, et al. No exonic mutations at GJB2, GJB3, GJB4, GJB6, ARS (Component B), and LOR genes responsible for a Chinese patient affected by progressive symmetric erythrokeratodermia with pseudoainhum. Int J Dermatol. 2014 Sep. 53 (9):1111-3. [Medline].

Morley SM, White MI, Rogers M, et al. A new, recurrent mutation of GJB3 (Cx31) in erythrokeratodermia variabilis. Br J Dermatol. 2005 Jun. 152(6):1143-8. [Medline].

Di WL, Monypenny J, Common JE, et al. Defective trafficking and cell death is characteristic of skin disease-associated connexin 31 mutations. Hum Mol Genet. 2002 Aug 15. 11(17):2005-14. [Medline].

van Steensel MA, Oranje AP, van der Schroeff JG, Wagner A, van Geel M. The missense mutation G12D in connexin30.3 can cause both erythrokeratodermia variabilis of Mendes da Costa and progressive symmetric erythrokeratodermia of Gottron. Am J Med Genet A. 2009 Feb 15. 149A(4):657-61. [Medline].

Korge BP, Ishida-Yamamoto A, Punter C, et al. Loricrin mutation in Vohwinkel’s keratoderma is unique to the variant with ichthyosis. J Invest Dermatol. 1997 Oct. 109(4):604-10. [Medline].

Maestrini E, Monaco AP, McGrath JA, et al. A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel’s syndrome. Nat Genet. 1996 May. 13(1):70-7. [Medline].

Cui Y, Yang S, Gao M, et al. Identification of a novel locus for progressive symmetric erythrokeratodermia to a 19.02-cM interval at 21q11.2-21q21.2. J Invest Dermatol. 2006 Sep. 126(9):2136-9. [Medline].

Shah K, Ansar M, Mughal ZU, Khan FS, Ahmad W, Ferrara TM, et al. Recessive progressive symmetric erythrokeratoderma results from a homozygous loss-of-function mutation of KRT83 and is allelic with dominant monilethrix. J Med Genet. 2017 Mar. 54 (3):186-189. [Medline].

Bourassa CV, Raskin S, Serafini S, Teive HA, Dion PA, Rouleau GA. A New ELOVL4 Mutation in a Case of Spinocerebellar Ataxia With Erythrokeratodermia. JAMA Neurol. 2015 Aug. 72 (8):942-3. [Medline].

Montpetit A, Cote S, Brustein E, et al. Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. PLoS Genet. 2008 Dec. 4(12):e1000296. [Medline].

Magyarlaki M, Drobnitsch I, Zombai E, Schneider I. [A case of erythrokeratodermia figurata variabilis successfully treated with tigason]. Z Hautkr. 1989 Oct 15. 64(10):881-2, 885-7. [Medline].

van de Kerkhof PC, Steijlen PM, van Dooren-Greebe RJ, Happle R. Acitretin in the treatment of erythrokeratodermia variabilis. Dermatologica. 1990. 181(4):330-3. [Medline].

Singh N, Thappa DM. Erythrokeratoderma variabilis responding to low-dose isotretinoin. Pediatr Dermatol. 2010 Jan-Feb. 27(1):111-3. [Medline].

Yoo S, Simzar S, Han K, Takahashi S, Cotliar R. Erythrokeratoderma variabilis successfully treated with topical tazarotene. Pediatr Dermatol. 2006 Jul-Aug. 23(4):382-5. [Medline].

Gabriele Richard, MD, FACMG Chief Medical Officer, GeneDx, Inc

Gabriele Richard, MD, FACMG is a member of the following medical societies: American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: GeneDx, a wholly owned subsidiary of Bioreference labs, a wholly owned subsidiary of Opko Health.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Harry Dao, Jr, MD Assistant Professor, Department of Dermatology, Baylor College of Medicine

Harry Dao, Jr, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Mark W Cobb, MD Consulting Staff, WNC Dermatological Associates

Mark W Cobb, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society of Dermatopathology

Disclosure: Nothing to disclose.

Erythrokeratodermia Variabilis et Progressiva

Research & References of Erythrokeratodermia Variabilis et Progressiva|A&C Accounting And Tax Services

19 Replies to “Erythrokeratodermia Variabilis et Progressiva”

  1. Pingback: how much is cialis
  2. Pingback: discount cialis
  3. Pingback: walmart pharmacy
  4. Pingback: online pharmacy
  5. Pingback: Cialis in usa
  6. Pingback: Buy cheap cialis
  7. Pingback: buy levitra
  8. Pingback: vardenafil online
  9. Pingback: cheap levitra
  10. Pingback: slot machine games
  11. Pingback: viagra cheap
  12. Pingback: instant loans
  13. Pingback: short term loans
  14. Pingback: viagra pills
  15. Pingback: cialis 5 mg
  16. Pingback: new cialis

Leave a Reply